Jaroslaw P Maciejewski

List of Publications by Citations

314 papers	7,694 citations	37 h-index	85 g-index
328 ext. papers	9,848 ext. citations	5 avg, IF	5.59 L-index

#	Paper	IF	Citations
314	Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*, **2012**, 120, 2454-65	2.2	1799
313	Somatic STAT3 mutations in large granular lymphocytic leukemia. *New England Journal of Medicine*, **2012**, 366, 1905-13	59.2	535
312	The pathophysiology of acquired aplastic anemia. *New England Journal of Medicine*, **1997**, 336, 1365-72	59.2	417
311	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. *New England Journal of Medicine*, **2015**, 373, 35-47	59.2	361
310	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. *Blood*, **2012**, 120, 3048-57	2.2	285
309	Dynamics of clonal evolution in myelodysplastic syndromes. *Nature Genetics*, **2017**, 49, 204-212	36.3	228
308	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. *Cancer Cell*, **2015**, 27, 658-70	24.3	228
307	In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. *Lancet, The*, **2004**, 364, 355-64	40	192
306	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood*, **2017**, 129, 2347-2358	2.2	184
305	Genetic alterations of the cohesin complex genes in myeloid malignancies. *Blood*, **2014**, 124, 1790-8	2.2	151
304	Wild-type and mutated IDH1/2 enzymes and therapy responses. *Oncogene*, **2018**, 37, 1949-1960	9.2	127
303	Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. *British Journal of Haematology*, **2009**, 146, 479-88	4.5	118
302	Whole genome scanning as a cytogenetic tool in hematologic malignancies. *Blood*, **2008**, 112, 965-74	2.2	116
301	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. *Cancer Research*, **2015**, 75, 4790-802	10.1	108
300	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. *Journal of Experimental Medicine*, **2015**, 212, 1819-32	16.6	106
299	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1846, 326-41	11.2	93
298	SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. *Blood*, **2011**, 117, 6876-84	2.2	88

297	STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. *Blood*, **2013**, 122, 2453-9	2.2	87
296	Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. *Journal of Clinical Investigation*, **2014**, 124, 4529-38	15.9	87
295	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. *Blood*, **2015**, 126, 907-907	2.2	73
294	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood*, **2020**, 136, 157-170	2.2	72
293	Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. *Leukemia*, **2018**, 32, 2250-2262	10.7	70
292	Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. *Journal of Experimental Medicine*, **2015**, 212, 1967-85	16.6	65
291	Evolution of clonal cytogenetic abnormalities in aplastic anemia. *Leukemia and Lymphoma*, **2004**, 45, 433-40	1.9	63
290	Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?". *Journal of Clinical Investigation*, **2000**, 106, 637-41	15.9	63
289	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nature Communications*, **2017**, 8, 15102	17.4	61
288	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. *Haematologica*, **2015**, 100, 91-9	6.6	61
287	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. *Journal of Clinical Investigation*, **2018**, 128, 4260-4279	15.9	61
286	Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. *Nature Immunology*, **2017**, 18, 236-245	19.1	60
285	Mutations in G protein □subunits promote transformation and kinase inhibitor resistance. *Nature Medicine*, **2015**, 21, 71-5	50.5	60
284	Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. *Clinical Cancer Research*, **2018**, 24, 1705-1715	12.9	53
283	High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. *Blood*, **2016**, 128, 2465-2468	2.2	51
282	Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. *Blood*, **2013**, 122, 4077-85	2.2	50
281	Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. *Blood*, **2011**, 118, 4384-93	2.2	50
280	Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-B gene network. *Cell Reports*, **2014**, 8, 1328-38	10.6	46

279	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). *Leukemia and Lymphoma*, **2018**, 59, 416-422	1.9	42
278	mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Advances*, **2019**, 3, 922-933	7.8	39
277	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. *Blood*, **2020**, 136, 1851-1862	2.2	34
276	Hematopoietic stem cells in aplastic anemia. *Archives of Medical Research*, **2003**, 34, 520-7	6.6	34
275	Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. *Blood*, **2004**, 104, 3782-8	2.2	34
274	Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. *Folia Histochemica Et Cytobiologica*, **2007**, 45, 5-14	1.4	34
273	Origins of myelodysplastic syndromes after aplastic anemia. *Blood*, **2017**, 130, 1953-1957	2.2	32
272	Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. *Haematologica*, **2009**, 94, 1407-14	6.6	32
271	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. *Haematologica*, **2016**, 101, e224-7	6.6	30
270	Consequences of mutant TET2 on clonality and subclonal hierarchy. *Leukemia*, **2018**, 32, 1751-1761	10.7	30
269	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. *Nature Communications*, **2019**, 10, 5386	17.4	29
268	Rational management approach to pure red cell aplasia. *Haematologica*, **2018**, 103, 221-230	6.6	29
267	DDX41-related myeloid neoplasia. *Seminars in Hematology*, **2017**, 54, 94-97	4	28
266	Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. *Annals of Hematology* , **2020**, 99, 1505-1514	3	27
265	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. *Journal of Clinical Investigation*, **2017**, 127, 3527-3542	15.9	26
264	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. *Blood*, **2018**, 132, 2100-2103	2.2	26
263	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 183-198	11.2	25
262	Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. *Journal of Leukocyte Biology*, **2008**, 83, 589-601	6.5	25

261	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. *Oncotarget*, **2017**, 8, 6483-6495	3.3	24
260	Germline loss-of-function and alterations in adult myelodysplastic syndromes. *Blood*, **2018**, 132, 2309-2313	17.2	23
259	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. *Blood Cancer Journal*, **2018**, 8, 4	7	21
258	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. *Blood*, **2020**, 136, 2249-2262	2.2	21
257	Immune pathophysiology of aplastic anemia. *International Journal of Hematology*, **2002**, 76 Suppl 1, 207-14	1.5	20
256	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. *Leukemia*, **2019**, 33, 2842-2853	10.7	19
255	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. *Leukemia and Lymphoma*, **2015**, 56, 3437-9	1.9	19
254	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. *Cancer Research*, **2020**, 80, 2031-2044	10.1	19
253	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. *Leukemia*, **2021**, 35, 1023-1036	10.7	19
252	Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). *Genomics, Proteomics and Bioinformatics*, **2018**, 16, 172-186	6.5	18
251	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. *Haematologica*, **2015**, 100, e434-7	6.6	18
250	Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. *PLoS ONE*, **2015**, 10, e0145394	3.7	18
249	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. *Blood Advances*, **2019**, 3, 339-349	7.8	18
248	Molecular pathogenesis of disease progression in MLL-rearranged AML. *Leukemia*, **2019**, 33, 612-624	10.7	18
247	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. *Bone Marrow Transplantation*, **2019**, 54, 1281-1286	4.4	17
246	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*, **2020**, 136, 698-714	2.2	16
245	ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. *Blood*, **2014**, 123, 3675-7	2.2	16
244	Myb expression is critical for myeloid leukemia development induced by Setbp1 activation. *Oncotarget*, **2016**, 7, 86300-86312	3.3	16

243	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. *Blood Advances*, **2019**, 3, 4228-4237	7.8	16
242	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia*, **2020**, 34, 957-962	10.7	16
241	Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. *American Journal of Hematology*, **2016**, 91, 185-92	7.1	15
240	Synergistic effect of major histocompatibility complex class I-related chain a and human leukocyte antigen-DPB1 mismatches in association with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1835-40	4.7	14
239	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 3737-3746	2.2	14
238	Molecular features of early onset adult myelodysplastic syndrome. *Haematologica*, **2017**, 102, 1028-1034	6.6	13
237	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. *Communications Biology*, **2020**, 3, 493	6.7	13
236	Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. *Oncotarget*, **2018**, 9, 2050-2057	3.3	12
235	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. *Blood*, **2021**, 137, 3685-3689	22	12
234	Subclonal STAT3 mutations solidify clonal dominance. *Blood Advances*, **2019**, 3, 917-921	7.8	12
233	Distinct clinical and biological implications of in myeloid neoplasms. *Blood Advances*, **2019**, 3, 2164-2178	7.8	12
232	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. *American Journal of Hematology*, **2019**, 94, E37-E41	7.1	12
231	Complex landscape of alternative splicing in myeloid neoplasms. *Leukemia*, **2021**, 35, 1108-1120	10.7	12
230	The functional mechanisms of mutations in myelodysplastic syndrome. *Leukemia*, **2019**, 33, 2779-2794	10.7	11
229	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. *American Journal of Hematology*, **2016**, 91, 406-9	7.1	11
228	Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 66-72	3.1	10
227	Molecular pathogenesis of myelodysplastic syndromes. *Translational Medicine @ UniSa*, **2014**, 8, 19-30	0.5	10
226	Genomics of therapy-related myeloid neoplasms. *Haematologica*, **2020**, 105, e98-e101	6.6	10

225	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. *Leukemia*, **2021**, 35, 1365-1379	10.7	10
224	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer*, **2016**, 16, 652	4.8	10
223	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. *Journal of Biomedical Informatics*, **2015**, 58, 104-113	10.2	9
222	Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 97-104	3.1	9
221	and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. *Leukemia and Lymphoma*, **2019**, 60, 1587-1590	1.9	9
220	The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy. *British Journal of Haematology*, **2018**, 182, 730-733	4.5	9
219	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. *Blood*, **2019**, 134, 2091-2091	2.2	8
218	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *British Journal of Haematology*, **2020**, 188, 924-929	4.5	8
217	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. *Cancers*, **2020**, 12,	6.6	7
216	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 4336-4336	2.2	7
215	Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis. *ELife*, **2019**, 8,	8.9	7
214	How I manage acquired pure red cell aplasia in adults. *Blood*, **2021**, 137, 2001-2009	2.2	7
213	New drugs for pharmacological extension of replicative life span in normal and progeroid cells. *Npj Aging and Mechanisms of Disease*, **2019**, 5, 2	5.5	7
212	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. *Blood*, **2021**, 138, 1928-1938	2.2	7
211	Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated to Disrupt Myeloid Differentiation in Myeloid Malignancies. *Clinical Cancer Research*, **2019**, 25, 2513-2522	12.9	6
210	Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. *British Journal of Haematology*, **2018**, 183, 133-136	4.5	6
209	Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. *Leukemia*, **2018**, 32, 2507-2511	12.7	6
208	Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. *Cell Stem Cell*, **2021**, 28, 1966-1981.e6	18	6

207	Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure. *British Journal of Haematology*, **2019**, 185, 935-939	4.5	5
206	A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).. *Blood*, **2009**, 114, 3797-3797	2.2	5
205	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. *Blood*, **2015**, 126, 1662-1662	2.2	5
204	Distinctive and common features of moderate aplastic anaemia. *British Journal of Haematology*, **2020**, 189, 967-975	4.5	4
203	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. *Blood*, **2011**, 118, 400-400	2.2	4
202	The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed. *Blood*, **2016**, 128, 444-444	2.2	4
201	Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. *Cell Reports*, **2021**, 35, 108989	10.6	4
200	Novel invariant features of Good syndrome. *Leukemia*, **2021**, 35, 1792-1796	10.7	4
199	Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. *British Journal of Haematology*, **2018**, 182, 373-383	4.5	4
198	TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. *Seminars in Hematology*, **2021**, 58, 27-34	4	4
197	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *British Journal of Haematology*, **2020**, 189, 318-322	4.5	3
196	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. *Blood*, **2019**, 134, 844-844	2.2	3
195	Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. *Blood*, **2019**, 134, 842-842	2.2	3
194	High Density SNP Arrays Reveal That Distinct Clonal Lesions Including Uniparental Disomy Can Be Detected in a Proportion of Patients with Aplastic Anemia with Normal Metaphase Cytogenetics.. *Blood*, **2006**, 108, 125-125	2.2	3
193	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. *Blood*, **2012**, 120, 1696-1696	2.2	3
192	The Role of LUC7L2 in Splicing and MDS. *Blood*, **2016**, 128, 5504-5504	2.2	3
191	Rare germline variant contributions to myeloid malignancy susceptibility. *Leukemia*, **2020**, 34, 1675-1678	10.7	3
190	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. *Blood*, **2021**, 138, 1885-1895	2.2	3

189	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. *Blood Cells, Molecules, and Diseases* , **2021**, 87, 102528	2.1	3
188	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. *Leukemia*, **2021**, 35, 2431-2434	10.7	3
187	Introduction: molecular pathogenesis of hematologic malignancies. *Seminars in Oncology*, **2012**, 39, 9-12	5.5	2
186	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. *SAGE Open Medical Case Reports*, **2013**, 1, 2050313X13498709	0.7	2
185	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. *Blood*, **2019**, 134, 4238-4238	2.2	2
184	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 880-880	2.2	2
183	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. *Blood*, **2020**, 136, 33-35	2.2	2
182	Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms. *Blood*, **2020**, 136, 38-40	2.2	2
181	A Decision Analysis To Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes.. *Blood*, **2005**, 106, 2533-2533	2.2	2
180	SNP Array-Based Analysis of Chromosome 17 Reveals Biallelic TP53 Mutations Due to Uniparental Disomy 17p in Advanced MDS and AML with Cooperating Deletions of Chromosomes 5 and 7. *Blood* , **2008**, 112, 2521-2521	2.2	2
179	Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction. *Blood*, **2011**, 118, 457-457	2.2	2
178	Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. *Blood*, **2015**, 126, 2507-2507	2.2	2
177	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. *Blood*, **2016**, 128, 4301-4301	2.2	2
176	The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. *Blood*, **2021**,	2.2	2
175	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. *Blood Cancer Journal*, **2021**, 11, 187	7	2
174	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2017**, 130, 779-779	2.2	2
173	Expression of MICA by Granulocytes in Neutropenia Due to Large Granular Lymphocyte Leukemia Points towards Cytotoxicity Exerted Via NKG2D on Clonal Cytotoxic T Cells.. *Blood*, **2008**, 112, 1262-1262	2.2	2
172	Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	2

171	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738	1.9	2
170	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 113-118	2	2
169	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. *JCI Insight*, **2021**, 6,	9.9	2
168	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. *Blood Advances*, **2021**, 5, 4361-4369	7.8	2
167	Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. *Cancers*, **2021**, 13,	6.6	2
166	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes.. *Nature Communications*, **2022**, 13, 1038	17.4	2
165	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8 T-cell large granular lymphocytic leukemia.. *Nature Communications*, **2022**, 13, 1981	17.4	2
164	Chronic myeloid leukemia: Two mysteries. *Leukemia Research*, **2019**, 79, 3-5	2.7	1
163	5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. *Haematologica*, **2020**, 105, e213-e215	6.6	1
162	Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. *British Journal of Haematology*, **2020**, 189, e133-e137	4.5	1
161	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. *Blood*, **2020**, 136, 17-18	2.2	1
160	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. *Blood*, **2020**, 136, 13-14	2.2	1
159	Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders. *Blood*, **2020**, 136, 29-30	2.2	1
158	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.. *Journal of Clinical Investigation*, **2022**,	15.9	1
157	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2696-2696	2.2	1
156	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia. *Blood*, **2019**, 134, 914-914	2.2	1
155	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. *Blood*, **2020**, 136, 8-8	2.2	1
154	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. *Blood*, **2020**, 136, 31-32	2.2	1

153	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. *Blood*, **2020**, 136, 2-2	2.2	1
152	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. *Blood*, **2020**, 136, 32-33	2.2	1
151	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. *Blood*, **2020**, 136, 1-1	2.2	1
150	Phosphatidylinositol-3-Phosphate Kinase Pathway Activation Protects Leukemic Large Granular Lymphocytes from Undergoing Homeostatic Apoptosis.. *Blood*, **2005**, 106, 739-739	2.2	1
149	Identification of Chromosomal Abnormalities in Healthy Bone Marrow Using 250K SNP Arrays.. *Blood*, **2006**, 108, 2076-2076	2.2	1
148	SNP-A Based Karyotyping Facilitates Improved Mapping of Deletions and Uniparental Disomy within the Long Arm of Chromosome 5 in Myeloid Disorders.. *Blood*, **2007**, 110, 2435-2435	2.2	1
147	Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients.. *Blood*, **2007**, 110, 2450-2450	2.2	1
146	Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome. *Blood*, **2008**, 112, 1038-1038	2.2	1
145	C-Cbl but Not TET2 Mutations Are Present in Patients with Juvenile Myelomonocytic Leukemia.. *Blood*, **2009**, 114, 420-420	2.2	1
144	Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q). *Blood*, **2010**, 116, 4016-4016	2.2	1
143	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2012**, 120, 1260-1260	2.2	1
142	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2012**, 120, 1973-1973	2.2	1
141	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. *Blood*, **2015**, 126, 1645-1645	2.2	1
140	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. *Blood*, **2016**, 128, 1659-1659	2.2	1
139	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. *Blood*, **2021**, 138, 610-610	2.2	1
138	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. *Blood*, **2021**, 138, 3486-3486	2.2	1
137	Polarized CTL Responses Detected in Patients with Autoimmune Neutropenia.. *Blood*, **2004**, 104, 1459-1459	2.2	1
136	Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome.. *Blood*, **2005**, 106, 369-369	2.2	1

135	Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).. *Blood*, **2006**, 108, 3012-3012	2.2	1
134	Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets. *Blood*, **2019**, 134, 1703-1703	2.2	1
133	Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2553-2553	2.2	1
132	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. *Journal of Clinical Oncology*, **2015**, 33, 11047-11047	2.2	1
131	Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution. *Blood*, **2008**, 112, 599-599	2.2	1
130	Investigations of Genetic Risk Factors in MDS and AML Using High- Density 6.0 Affymetrix Arrays. *Blood*, **2008**, 112, 638-638	2.2	1
129	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. *Leukemia and Lymphoma* , **2020**, 61, 1242-1245	1.9	1
128	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. *Leukemia*, **2020**, 34, 327-330	10.7	1
127	Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. *Leukemia*, **2021**, 35, 1176-1187	10.7	1
126	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. *Blood Cells, Molecules, and Diseases*, **2021**, 91, 102595	2.1	1
125	Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations. *Blood*, **2020**, 136, 7-8	2.2	0
124	Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features. *Blood*, **2020**, 136, 34-35	2.2	0
123	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia.. *Seminars in Hematology*, **2022**, 59, 47-53	4	0
122	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia.. *Hematological Oncology*, **2022**,	1.3	0
121	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. *Blood*, **2016**, 128, 1505-1505	2.2	0
120	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. *Blood*, **2021**, 138, 3666-3666	2.2	0
119	Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia. *Blood*, **2021**, 138, 375-375	2.2	0
118	A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. *Blood*, **2021**, 138, 1249-1249	2.2	0

117	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2021**, 138, 603-603	2.2	0
116	Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies. *Blood*, **2021**, 138, 3985-3985	2.2	0
115	Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation.. *IScience*, **2022**, 25, 103679	6.1	0
114	MPO as a Novel Susceptibility Gene in Myeloid Malignancies. *Blood*, **2019**, 134, 5402-5402	2.2	0
113	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. *Blood*, **2015**, 126, 1350-1350	2.2	0
112	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. *Leukemia*, **2021**, 35, 3324-3328	10.7	0
111	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 917.e1-917.e9		0
110	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leukemia and Lymphoma*, **2021**, 1-6	1.9	0
109	T-cell large granular lymphocytic leukemia associated with inclusion body myositis. *International Journal of Laboratory Hematology*, **2021**,	2.5	0
108	Aplastic anemia: Quo vadis?. *Seminars in Hematology*, **2022**, 59, 54-55	4	0
107	A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase. *Blood*, **2020**, 136, 32-33	2.2	
106	Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2020**, 136, 8-8	2.2	
105	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. *Blood*, **2020**, 136, 25-25	2.2	
104	Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). *Blood*, **2020**, 136, 54-55	2.2	
103	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. *Blood*, **2020**, 136, 21-22	2.2	
102	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2020**, 136, 2-3	2.2	
101	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. *Blood*, **2020**, 136, 28-28	2.2	
100	The Genomic Landscape of Wilms Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. *Blood*, **2020**, 136, 28-28	2.2	

99	Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive. *Blood*, **2020**, 136, 26-27	2.2
98	Molecular and Expression Characterization of Monosomy 7 and Del(7q). *Blood*, **2020**, 136, 33-33	2.2
97	Implication of Piga Genotype on Clinical Features of PNH. *Blood*, **2020**, 136, 34-35	2.2
96	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. *Blood*, **2020**, 136, 34-35	2.2
95	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. *Blood*, **2020**, 136, 20-21	2.2
94	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. *Blood*, **2020**, 136, 2-3	2.2
93	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. *Blood*, **2020**, 136, 21-21	2.2
92	Role of Oligoadenylate Synthetases in Myeloid Neoplasia. *Blood*, **2020**, 136, 29-30	2.2
91	TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity. *Blood*, **2020**, 136, 2-3	2.2
90	Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia. *Blood*, **2020**, 136, 36-36	2.2
89	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2021**, 138, 602-602	2.2
88	Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage. *Blood*, **2021**, 138, 1148-1148	2.2
87	A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia. *Blood*, **2021**, 138, 786-786	2.2
86	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2021**, 138, 4303-4303	2.2
85	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. *Blood*, **2021**, 138, 1093-1093	2.2
84	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. *Blood*, **2021**, 138, 4467-4467	2.2
83	Prospective Molecular Identification of Alloreactive CTL Clones in Allogeneic Hematopoietic Stem Cell Transplantation.. *Blood*, **2004**, 104, 4972-4972	2.2
82	Differential Comparative Genomic Hybridization Analysis of Normal and Glycosyl Phosphatidyl Inositol Deficient Clones in Paroxysmal Noctorunal Hemoglobinuria.. *Blood*, **2004**, 104, 2831-2831	2.2

81	Pathologic Clonal CTLResponses - Non Random Nature of the TCR Restriction in LGL Leukemia.. *Blood*, **2004**, 104, 3241-3241	2.2
80	A Pilot Application of SELDI Serum Proteomics in Bone Marrow Failure Syndromes.. *Blood*, **2004**, 104, 2822-2822	2.2
79	KIR Gene Distribution in Hematologic Disorders.. *Blood*, **2004**, 104, 1624-1624	2.2
78	In Search for the Specificity of Clonal CTL in T-LGL Leukemia - Generation of Soluble LGL-Derived T Cell Receptor.. *Blood*, **2004**, 104, 4645-4645	2.2
77	High-Resolution Genomic Scan for Cryptic Chromosomal Lesions in MDS and AML.. *Blood*, **2004**, 104, 3427-3427	2.2
76	Efficient Identification of T-Cell Clones Associated with Graft-Versus-Host Disease (GvHD) in Target Tissue for Subsequent Detection in Peripheral Blood.. *Blood*, **2004**, 104, 2243-2243	2.2
75	Molecular Identification of Alloreactive CTL Precursors in Hematopoietic Stem Cell Transplantation.. *Blood*, **2005**, 106, 597-597	2.2
74	High-Resolution Genomic Arrays Facilitate Detection of Novel Cryptic Chromosomal Lesions in MDS.. *Blood*, **2005**, 106, 370-370	2.2
73	Immunogenetic Factors Determining Evolution of T-Cell Large Granular Lymphocyte Leukemia and Associated Cytopenias.. *Blood*, **2005**, 106, 2211-2211	2.2
72	Differential Expression of SLAM Family Receptor Markers in Normal Human Hematopoietic Stem Cells and Their Malignant Counterpart in MDS and AML.. *Blood*, **2006**, 108, 1897-1897	2.2
71	SNP-Array Karyotyping Reveals the Presence of Previously Cryptic Clonal Chromosomal Aberrations Including Segmental UPD in Patients with Fanconi Anemia.. *Blood*, **2007**, 110, 1678-1678	2.2
70	SNP-A Karyotyping Demonstrates a High Incidence of Segmental Uniparental Disomy in Patients with CMML and Shows Impact of Newly Identified Chromosomal Aberrations on Clinical Course.. *Blood*, **2007**, 110, 2428-2428	2.2
69	SNP-Array-Based Karyotyping Has Impact on Cytogenetic Diagnosis and Prognosis of Non-Core Binding Factor Primary and Secondary AML.. *Blood*, **2007**, 110, 597-597	2.2
68	Can Genomic Copy Number Variants Be a Part of Complex Genetic Traits Predisposing to Marrow Failure?.. *Blood*, **2007**, 110, 106-106	2.2
67	SNP Arrays Facilitate Genotyping of Non-Synonymous SNP in MDS To Identify Disease Susceptibility Loci.. *Blood*, **2007**, 110, 2421-2421	2.2
66	Decreased Expression of Membrane-Bound Proteinase 3 by a GPI-Deficient Granulocytes May Contribute to Thrombophilic Propensity in PNH.. *Blood*, **2007**, 110, 3673-3673	2.2
65	SNP Array Karyotyping Improves Detection Rate of Clonal Chromosomal Abnormalities in Refractory Anemia with Ringed Sideroblasts.. *Blood*, **2007**, 110, 4132-4132	2.2
64	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. *Blood*, **2017**, 130, 878-878	2.2

63	Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. *Blood*, **2018**, 132, 3866-3866	2.2
62	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. *Blood*, **2018**, 132, 4352-4352	2.2
61	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075	2.2
60	Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action. *Blood*, **2018**, 132, 1302-1302	2.2
59	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. *Blood*, **2018**, 132, 3074-3074	2.2
58	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1527-1527	2.2
57	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. *Blood*, **2018**, 132, 371-371	2.2
56	T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.. *Journal of Clinical Oncology*, **2019**, 37, e19072-e19072	2.2
55	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). *Blood*, **2019**, 134, 1281-1281	2.2
54	The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases. *Blood*, **2019**, 134, 769-769	2.2
53	Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity. *Blood*, **2019**, 134, 1279-1279	2.2
52	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 564-564	2.2
51	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 5043-5043	2.2
50	TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins. *Blood*, **2019**, 134, 1200-1200	2.2
49	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. *Blood*, **2019**, 134, 1226-1226	2.2
48	Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. *Blood*, **2019**, 134, 1572-1572	2.2
47	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2019**, 134, 3743-3743	2.2
46	Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI). *Blood*, **2019**, 134, 2089-2089	2.2

45	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595	2.2
44	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. *Blood*, **2019**, 134, 4271-4271	2.2
43	Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms. *Blood*, **2014**, 124, 3581-3581	2.2
42	Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. *Blood*, **2014**, 124, 784-784	2.2
41	Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia. *Blood*, **2015**, 126, 2216-2216	2.2
40	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. *Blood*, **2015**, 126, 435-435	2.2
39	Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. *Blood*, **2015**, 126, 2848-2848	2.2
38	Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes. *Blood*, **2015**, 126, 612-612	2.2
37	Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). *Blood*, **2015**, 126, 4491-4491	2.2
36	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. *Blood*, **2015**, 126, 611-611	2.2
35	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. *Blood*, **2016**, 128, 4293-4293	2.2
34	FISH and SNP-Array Karyotyping Improve the Detection of Recurrent Chromosomal Defects Including Del(5q), Monosomy 7, Del(7q), Trisomy 8, and Del(20q) in Myelodysplastic Syndromes.. *Blood*, **2008**, 112, 1483-1483	2.2
33	Progressive Chromatin Repression and Promoter Methylation of a-catenin Correlates with AML Transformation in Patients with and without 5q Deletions.. *Blood*, **2008**, 112, 3369-3369	2.2
32	BACH2 Directly Regulates Expression of Foxp3 in UCB CD4+ T-Cells. *Blood*, **2008**, 112, 4760-4760	2.2
31	Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-□ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background. *Blood*, **2008**, 112, 4116-4116	2.2
30	SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS. *Blood*, **2008**, 112, 639-639	2.2
29	Alemtuzumab Shows Significant Efficacy in T-LGL Leukemia and Refractory Cases Are Due to GPI-Deficiency of LGL Clones.. *Blood*, **2008**, 112, 2038-2038	2.2
28	Identification of Genetic Polymorphisms Contributing to Risk in MDS Using Innovative GWAS Approaches.. *Blood*, **2009**, 114, 734-734	2.2

27	Reconciling Phenotype with Genotype in the MPN: Impact of SNP Array-Based Chromosomal Analysis.. *Blood*, **2009**, 114, 1893-1893	2.2
26	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. *Blood*, **2010**, 116, 3076-3076	2.2
25	SNP-A Karyotyping Provides Clinically Relevant Results In Myeloid Hematologic Disorders with Unsuccessful Routine Cytogenetic Testing.. *Blood*, **2010**, 116, 3374-3374	2.2
24	HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases. *Blood*, **2010**, 116, 1724-1724	2.2
23	Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH). *Blood*, **2010**, 116, 2001-2001	2.2
22	CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders.. *Blood*, **2010**, 116, 3396-3396	2.2
21	A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression.. *Blood*, **2010**, 116, 1687-1687	2.2
20	Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia.. *Blood*, **2010**, 116, 1171-1171	2.2
19	Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygozity on Chromosome 7 In Myeloid Malignancies. *Blood*, **2010**, 116, 297-297	2.2
18	Gene Alterations In Acute Megakaryoblastic Leukemia (AMKL): a Comparison of AMKL with and without Down Syndrome. *Blood*, **2010**, 116, 875-875	2.2
17	Clinical and Genomic Characterization of Chromosome 7 Lesions in Myeloid Malignancies,. *Blood*, **2011**, 118, 3549-3549	2.2
16	Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions. *Blood*, **2011**, 118, 2795-2795	2.2
15	A Novel View of Paroxysmal Nocturnal Hemoglobinuria (PNH) Pathogenesis: Do Pathologic PNH Hematopoietic Stem/Progenitor Cells (HSPCs) Displace Normal HSPCs From Their Niches in Bone Marrow Because They Are More Motile Due to Defective Adhesion and Enhanced Migratory Properties?. *Blood*, **2011**, 118, 732-732	2.2
14	Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA). *Blood*, **2011**, 118, 1726-1726	2.2
13	Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes. *Blood*, **2011**, 118, 2412-2412	2.2
12	Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology. *Blood*, **2011**, 118, 791-791	2.2
11	Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. *Blood*, **2011**, 118, 271-271	2.2
10	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2011**, 118, 2015-2015	2.2

9	A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,. *Blood*, **2011**, 118, 3830-3830	2.2
8	Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML),. *Blood*, **2011**, 118, 3566-3566	2.2
7	Pathogenesis of MONOSOMY 7 In BONE MARROW FAILURE SYNDROMES. *Blood*, **2011**, 118, 2411-2411	2.2
6	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities,. *Blood*, **2011**, 118, 4137-4137	2.2
5	Whole Exome Analysis Reveals Spectrum of Gene Mutations in Juvenile Myelomonocytic Leukemia. *Blood*, **2012**, 120, 170-170	2.2
4	Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-B. *Blood*, **2012**, 120, 557-557	2.2
3	Whole Exome Sequencing Detecting Kinesin Family Gene Defects In Myeloid Neoplasm. *Blood*, **2013**, 122, 2762-2762	2.2
2	Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies. *Blood*, **2013**, 122, 2807-2807	2.2
1	Dexrazoxane enhances efficacy of all- retinoic acid in acute myeloid leukemia patient blast cells and cell lines. *Leukemia and Lymphoma*, **2021**, 62, 473-477	1.9